Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2022-10-24 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
第五届监事会第二十四次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Shenzhen Salubris Pharmaceuticals Co., Ltd. It reports the approval of the company's 2022 third quarter report and other internal governance matters. The text explicitly states that the 2022 third quarter report was reviewed and approved, but the report itself is not included. Instead, it references where the full report can be found (China Securities Journal, Securities Times, and cninfo.com.cn). The document is short (1386 characters) and serves as an official announcement of the Supervisory Board's meeting decisions, not the financial report itself. Therefore, it is not an Interim/Quarterly Report (IR) but rather a Regulatory Filing (RNS) or possibly a Report Publication Announcement (RPA). However, since it contains detailed resolutions and approvals by the Supervisory Board, it fits best under Regulatory Filings (RNS) as a formal disclosure of meeting resolutions and approvals related to financial reports and company policies.
2022-10-24 Chinese
关于开展金融衍生品交易的可行性分析报告
Capital/Financing Update Classification · 95% confidence The document is a detailed feasibility analysis report regarding the company's plan to engage in financial derivatives trading to hedge foreign exchange and interest rate risks. It includes descriptions of the necessity, scope, risk analysis, risk control measures, accounting policies, and impact on the company. There is no indication that this is an announcement of a report publication or a brief summary. The document is not a certification or attestation. It is not a regulatory filing or announcement but a substantive internal or external report analyzing a specific financial activity. The content is focused on financial risk management and strategy rather than financial results or governance changes. Therefore, it fits best under the category of Capital/Financing Update (CAP), as it relates to updates on the company's financing activities and risk management strategies involving financial derivatives.
2022-10-24 Chinese
第五届董事会第三十三会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 33rd meeting of the 5th Board of Directors of Shenzhen Salubris Pharmaceuticals Co., Ltd. It includes details about the meeting date, attendance, and voting results on several agenda items, including approval of the company's 2022 Q3 report, adoption of a financial derivatives trading management system, and authorization to conduct financial derivatives trading. The document is structured as a board meeting resolution announcement and does not contain the actual financial report or detailed financial data. It also references where the 2022 Q3 report and other documents can be found but does not include them. Therefore, this is a Board/Management Information announcement regarding board meeting resolutions and decisions, not the report itself or a regulatory filing of the report.
2022-10-24 Chinese
关于SAL0108临床试验进展的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the progress of a clinical trial for a pharmaceutical product (SAL0108). It provides details about the clinical trial phase completion, the study design, and future expectations. There is no financial data, no mention of annual or quarterly financial results, no regulatory certifications, or management changes. The document is an announcement of clinical trial progress, which is a regulatory update related to the company's drug development pipeline. It does not fit into financial report categories like Annual Report (10-K), Interim Report (IR), or Earnings Release (ER). It is not a legal proceeding or merger announcement. Given the nature of the content and the lack of financial or governance data, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory announcements that do not fit other categories.
2022-10-14 Chinese
关于控股股东部分股份质押及解除质押的公告
Major Shareholding Notification Classification · 95% confidence The document is a formal announcement regarding the pledge and release of shares by the controlling shareholder of Shenzhen Salubris Pharmaceuticals Co., Ltd. It details the number of shares pledged, released, and the current status of pledged shares. The content focuses on share pledging activities and related disclosures, without any financial statements, earnings data, or management discussion. It is not a full financial report, earnings release, or management report. The document is a regulatory announcement about share pledging activities by a major shareholder, which fits the category of Major Shareholding Notification (MRQ). The document length is 2312 characters, which is typical for such announcements. Therefore, the appropriate classification is MRQ.
2022-10-12 Chinese
关于SAL056临床试验进展的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the progress of a clinical trial for a drug (SAL056). It provides detailed information about the clinical trial phase completion, the drug's intended use, and future plans. The document is relatively short (1137 characters) and is an update on a specific project rather than a financial report or regulatory filing. It does not contain financial statements, earnings data, or governance information. It is an announcement about clinical progress, which does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is also not a regulatory filing or certification. The best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2022-10-10 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.